文献速递产科母胎医学

美国胎盘植入谱系疾病的国家趋势、特征与结局

Trends, characteristics, and outcomes of placenta accreta spectrum: a national study in the United States.
PubMed 文献 · Am J Obstet Gynecol · 2021-04-21

研究发现该病发生率每季度增加2.1%,且植入性(increta)和穿透性(percreta)胎盘植入者的手术并发症和死亡率显著高于非植入组。

要点

  • 胎盘植入谱系疾病发生率从0.27%升至0.32%,每季度增加2.1%。
  • 植入性和穿透性胎盘植入者子宫切除率分别达82.4%和78.3%。
  • 穿透性胎盘植入者的手术死亡风险是非植入组的32.1倍。

核心结论

  • 胎盘植入谱系疾病发生率呈上升趋势,且不同亚型的患者特征和结局存在差异。
  • 植入性和穿透性胎盘植入者的手术并发症和死亡风险显著增高。

研究设计与样本

  • 基于美国国家住院样本的回顾性观察性研究。
  • 采用广义估计方程多因素分析和线性分段回归评估趋势。

主要发现

  • 共纳入2,727,477例剖宫产,其中8030例(0.29%)诊断为胎盘植入谱系疾病。
  • 胎盘植入谱系疾病发生率从0.27%上升至0.32%,每季度增加2.1%(P=.004)。
  • 植入性和穿透性胎盘植入者的子宫切除率分别为82.4%和78.3%,非植入组为0.4%(P<.001)。
  • 穿透性胎盘植入者的手术死亡比值比为32.1,植入性为19.9。

关键数值与推荐

  • 胎盘植入谱系疾病患者中,胎盘植入(accreta)最常见(n=6205,0.23%),其次为穿透性(percreta,n=1060,0.04%)和植入性(increta,n=765,0.03%)。
  • 植入性和穿透性胎盘植入者的剖宫产孕周中位数均为34周,胎盘植入者为36周,非胎盘植入谱系疾病者为39周(P<.001)。
  • 胎盘植入谱系疾病组的手术并发症发生率为78.3%,非植入组为10.6%;严重孕产妇并发症发生率分别为60.3%和3.1%。
  • 胎盘植入谱系疾病组的出血发生率为54.1%,非植入组为3.9%;凝血功能障碍发生率分别为5.3%和0.3%。
  • 胎盘植入谱系疾病组的死亡率为0.25%,非植入组为0.01%。

临床怎么用

  • 对于存在胎盘植入谱系疾病高危因素(如前置胎盘、既往剖宫产史、辅助生殖技术等)的孕妇,应提高警惕并加强产前诊断。
  • 植入性和穿透性胎盘植入者应转诊至具备多学科团队的大型城市教学医院进行管理。
  • 剖宫产术前应充分评估手术风险,做好大出血、子宫切除及多脏器损伤的应对准备。

局限性

  • 本研究为回顾性研究,依赖行政数据编码,可能存在诊断编码偏倚。
  • 未报告胎盘植入谱系疾病的具体诊断方法和产前诊断率。
  • 缺乏长期随访结局和新生儿结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although an infrequent occurrence, the placenta can adhere abnormally to the gravid uterus leading to significantly high maternal morbidity and mortality during cesarean delivery. Contemporary national statistics related to a morbidly adherent placenta, referred to as placenta accreta spectrum, are needed. OBJECTIVE: This study aimed to examine national trends, characteristics, and perioperative outcomes of women who underwent cesarean delivery for placenta accreta spectrum in the United States. STUDY DESIGN: This is a population-based retrospective, observational study querying the National Inpatient Sample. The study cohort included women who underwent cesarean delivery from October 2015 to December 2017 and had a diagnosis of placenta accreta spectrum. The main outcome measures were patient characteristics and surgical outcomes related to placenta accreta spectrum assessed by the generalized estimating equation on multivariable analysis. The temporal trend of placenta accreta spectrum was also assessed by linear segmented regression with log transformation. RESULTS: Of 2,727,477 cases who underwent cesarean delivery during the study period, 8030 (0.29%) had the diagnosis of placenta accreta spectrum. Placenta accreta was the most common diagnosis (n=6205, 0.23%), followed by percreta (n=1060, 0.04%) and increta (n=765, 0.03%). The number of placenta accreta spectrum cases increased by 2.1% every quarter year from 0.27% to 0.32% (P=.004). On multivariable analysis, (1) patient demographics (older age, tobacco use, recent diagnosis, higher comorbidity, and use of assisted reproductive technology), (2) pregnancy characteristics (placenta previa, previous cesarean delivery, breech presentation, and grand multiparity), and (3) hospital factors (urban teaching center and large bed capacity hospital) represented the independent characteristics related to placenta accreta spectrum (all, P<.05). The median gestational age at cesarean delivery was 36 weeks for placenta accreta and 34 weeks for both placenta increta and percreta vs 39 weeks for non-placenta accreta spectrum cases (P<.001). On multivariable analysis, cesarean delivery complicated by placenta accreta spectrum was associated with increased risk of any surgical morbidities (78.3% vs 10.6%), Centers for Disease Control and Prevention-defined severe maternal morbidity (60.3% vs 3.1%), hemorrhage (54.1% vs 3.9%), coagulopathy (5.3% vs 0.3%), shock (5.0% vs 0.1%), urinary tract injury (8.3% vs 0.2%), and death (0.25% vs 0.01%) compared with cesarean delivery without placenta accreta spectrum. When further analyzed by subtype, cesarean delivery for placenta increta and percreta was associated with higher likelihood of hysterectomy (0.4% for non-placenta accreta spectrum, 45.8% for accreta, 82.4% for increta, 78.3% for percreta; P<.001) and urinary tract injury (0.2% for non-placenta accreta spectrum, 5.2% for accreta, 11.8% for increta, 24.5% for percreta; P<.001). Moreover, women in the placenta increta and percreta groups had markedly increased risks of surgical mortality compared with those without placenta accreta spectrum (increta, odds ratio, 19.9; and percreta, odds ratio, 32.1). CONCLUSION: Patient characteristics and outcomes differ across the placenta accreta spectrum subtypes, and women with placenta increta and percreta have considerably high surgical morbidity and mortality risks. Notably, 1 in 313 women undergoing cesarean delivery had a diagnosis of placenta accreta spectrum by the end of 2017, and the incidence seems to be higher than reported in previous studies.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Matsuzaki S, Mandelbaum RS, Sangara RN, et al. Trends, characteristics, and outcomes of placenta accreta spectrum: a national study in the United States. Am J Obstet Gynecol. 2021. PMID: 33894149. doi:10.1016/j.ajog.2021.04.233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。